David A. Brindley

Learn More
1The Advanced Centre for Biochemical Engineering, University College London, London, UK 2The Harvard Stem Cell Institute, Cambridge, MA, USA 3Harvard Business School, Boston, MA, USA 4London Regenerative Medicine Network, London, UK 5Harvard Medical School, Center for Excellence in Vascular Biology, Boston, MA, USA 6Future Medicine Ltd, London, UK 7Lonza(More)
volume 32 NumBeR 8 AuGuST 2014 nature biotechnology Although it may be beneficial for competing industry that no single entity dominates market access to all fundamental iPSC technologies, congestion of patents related to broadly enabling technologies, referred to as a ‘patent thicket’, has the potential to bottleneck innovation. If ownership of overlapping(More)
OBJECTIVE To investigate whether placebo controls should be used in the evaluation of surgical interventions. DESIGN Systematic review. DATA SOURCES We searched Medline, Embase, and the Cochrane Controlled Trials Register from their inception to November 2013. STUDY SELECTION Randomised clinical trials comparing any surgical intervention with placebo.(More)
Abstract The meeting "Commercialization of Your Regenerative Medicine Research: Lessons from Spin Out Successes" was hosted by the Oxbridge Biotech Roundtable (OBR) (Oxford, UK) at the University of Oxford in February, 2013, and attracted a multi-stakeholder audience spanning academia and industry. The event featured case studies from Gregg Sando, CEO, Cell(More)
Today, a range of products based on genomics, proteomics and metabolomics have facilitated the development of 'stratified' medicines and companion diagnostics. This investigation profiles a series of targeted medicines and corresponding diagnostics, and their role(s) in supporting evidence-based medicine. Despite their potential benefits we found that(More)
The cell therapy industry (CTI) is presently a small but potentially rapidly growing new global healthcare sector. Success is totally dependent on resolving a number of factors unique to cells as therapies, including: manufacturing, enabling technologies, regulation, reimbursement and essential infrastructure. To understand how to solve these challenges in(More)
Stock market volatility in the cell therapy industry has greatly hindered the investment necessary to fund translational therapies. Here, we review the volatility of leading companies and suggest that a distinct industry is maturing to a point at which the volatility should subside, providing a more attractive environment for future growth.
Induced pluripotent stem cells (iPSCs) have the potential to transform drug discovery and healthcare in the 21(st) century. However, successful commercialization will require standardized manufacturing platforms. Here we highlight the need to define standardized practices for iPSC generation and processing and discuss current challenges to the robust(More)
The aim of this perspective piece is to highlight how the "social perception" and "financial reality" of regenerative medicine may act to hinder its evolution into the principal health-care option for the future. We also consider the role of the consumer and the need for increased public awareness. Furthermore, we consider the effects of the changing social(More)